CSP is one of the most widely characterized malaria vaccine candidate antigens, and the only one whose components have gone so far as completion of a successful phase II b clinical trial [12,45], the generation of relevant genetic, epidemiologic and immunologic data for the CSP gene is important, particularly for regions of low malaria endemicity. The gene discussed is DNAJC5; the disease is malaria.